Saturday, July 25, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
HEALTHCARE & FDACMS's Star Ratings Overhaul Rescues the Biggest Medicare Advantage Insurers — For NowtodayDEFENSEMercury Systems: The Toll Booth Every Drone and Missile Program Has to Pass Through4 weeks agoTRADE & TARIFFSTariffs on Indian Pharma Are Coming — and U.S. Generic Drug Buyers Will Pay the BilltodayDEFENSEKratos vs. AeroVironment: Which One Actually Wins the Cheap-Drone-Swarm Pivot4 weeks agoMARKETSChina's $765M Antitrust Fine on Trip.com Is a Warning Shot for U.S.-Listed Chinese Consumer StockstodayENERGYLNG Export Licenses: How a FERC Approval Mints a Monopoly4 weeks agoDEFENSEPentagon's $7B Oracle Software Deal Is One of the Cleanest Defense-Tech Wins in YearstodayDEFENSERTX's Two-Front Bet: Why Iran Tensions and NATO's 5% Pledge Hit the Same Ticker Differently4 weeks agoDEFENSEThe U.S.-Iran War Is Costing $37.5B and Counting — Here's Where That Money GoesyesterdayENERGYThe SPR Refill Trade: Who Gets Paid When Washington Buys Oil4 weeks agoENERGYTrump Signs the Saudi Nuclear Deal — and U.S. Uranium and Reactor Companies Are the Quiet WinnersyesterdayDEFENSEChina's Rare-Earth Squeeze Will Hit Defense Primes Unevenly4 weeks agoCRYPTOThe Senate's Landmark Crypto Bill Creates Winners Inside the ETF and Exchange StackyesterdayDEFENSEIron Dome and the FMS Pipeline: How Middle East Tensions Fund Missile Defense Primes4 weeks agoWHITE HOUSETrump's Critical Minerals Order Cuts China Out of the Military Supply Chain — These Miners Fill the GapyesterdayDEFENSEThe Pentagon's AI Mandate: Why Defense Data Platforms Are Now a Weapons Program4 weeks agoDEFENSEOracle Lands a $7B Pentagon Software Contract — and the Market Should Take It SeriouslyyesterdayDEFENSELeidos Is the Quiet Beneficiary of Every "Modernize Federal IT" Executive Order4 weeks agoENERGYNRC Approves Holtec's Upgraded Spent Fuel Storage System — A Quiet Win for Nuclear's Capacity Expansion2 days agoDEFENSESole-Source vs. Full-and-Open: The Slow Bleed in LMT's F-35 Sustainment Machine4 weeks agoDEFENSEHouse Passes $1.15T Defense Bill — Missile Defense, Shipbuilding, and Next-Gen Air Get the Money2 days agoDEFENSEThe Hypersonic Arms Race Has a Bottleneck — and Three Contractors Own It4 weeks agoTRADE & TARIFFSTrump's 50% Canada Tariff Threat Keeps U.S. Aluminum Tight — Domestic Producers Win, Manufacturers Pay2 days agoDEFENSEThe Loser Nobody Names: Export Controls Squeeze Boeing From Both Sides4 weeks agoWHITE HOUSETrump's Critical Minerals Order Cuts China Out of the Defense Supply Chain — and Sends Money to U.S. Miners3 days agoDEFENSEThe Drone Proliferation Trade: Washington's Shift to Attritable Unmanned Systems Creates a Recurring Revenue Stream4 weeks agoCRYPTOWhite House Concedes Ethics Provision in Crypto Bill — Clearing the Last Roadblock for Stablecoin Legislation3 days agoDEFENSENATO's 2% Mandate Is a Revenue Stream Disguised as an Alliance Obligation4 weeks agoENERGYTrump's Saudi Nuclear Pact Without Enrichment Safeguards Heads to Congress — U.S. Uranium and Nuclear Services Names Are the Play3 days agoDEFENSEWho Actually Cashes In on 'Golden Dome': The Subcontractor Layer Behind LMT and RTX4 weeks agoTECHBosch's $225M CHIPS Act Award for Roseville Chips Away at U.S. Dependence on Asian Auto Semiconductors3 days agoDEFENSEHII Is a Congressional Appropriations Bet, Not a Navy Bet4 weeks agoHEALTHCARE & FDACMS Freezes $1 Billion in Medicaid Payments to California and Minnesota — Managed Care Insurers Face Revenue Gaps3 days agoDEFENSEWhen the Pentagon Classifies a Budget Line: The Black Budget Trade4 weeks agoWHITE HOUSETrump's Defense Supply Chain Order Tightens Waiver Rules — Domestic Parts Makers Win, Foreign-Sourced Primes Face Friction4 days agoDEFENSEThe FMS Loophole: How State Department Sign-Offs Insulate Defense Primes From Shutdown Risk4 weeks agoENERGYNew Jersey's Nuclear Energy Law Opens a Real Revenue Path for Small Reactor Developers4 days agoDEFENSESentinel vs. Columbia: The Nuclear Triad's Budget Is a Zero-Sum Game3 weeks agoDEFENSEPentagon's $80M Drone Defense Contract Points to the Counter-UAS Names Worth Watching4 days agoDEFENSEThe Nuclear Triad Upgrade Cycle: Three Legs, Three Winners, Decades of Locked-In Spending3 weeks agoDEFENSEU.S.-Iran Conflict Escalation Stalls Hormuz Shipping — Defense Contractors and Oil Majors Are the Immediate Read4 days agoTRADE & TARIFFSThe Tariff Refund Portal Is Open and Companies Are Cashing In — Nike and FedEx Are the Names to Watch3 weeks agoWHITE HOUSEWhite House Control Over Frontier AI Access Reshapes Who Wins the Model Race5 days agoTRADE & TARIFFSTrump's Fertilizer Tariff Suspension Cuts Input Costs for Farmers — and Squeezes Domestic Producers3 weeks agoENERGYNew Mexico's Pipeline Denial Puts Oracle's Data Center Expansion on Ice — and Highlights Every Hyperscaler's Power Risk5 days agoMARKETSSupreme Court Gives Trump FTC Firing Power — Antitrust Enforcement Just Got More Political3 weeks agoHEALTHCARE & FDACMS's Site-Neutral and 340B Reform Proposal Squeezes Hospital Margins and Lifts Independent Pharmacies5 days agoDEFENSEWhy L3Harris Is Really a Policy Stock, Not a Hardware Stock3 weeks agoDEFENSEU.S.-Iran Escalation and a Stalled Strait of Hormuz Are a Windfall for Tanker Owners and Defense Primes5 days agoDEFENSEThe F-35 Sustainment Lock-In: Why the Pentagon's Most Expensive Program Keeps Paying One Company Forever3 weeks agoTECHBosch's $225M CHIPS Award for Silicon Carbide Chips Is a Direct Threat to Wolfspeed's U.S. Market Share5 days agoDEFENSELockheed's $35B Interceptor Contract Is the Biggest Missile-Defense Payday in Years — Here's Who Else Gets Paid3 weeks agoHEALTHCARE & FDACMS's Site-Neutral and 340B Cuts Would Squeeze Hospital Systems and Hand Wins to Outpatient Rivals6 days agoWHITE HOUSETrump Suspends Fertilizer Tariffs — Farm Input Costs Drop and Ag Names Get a Quiet Tailwind3 weeks agoWHITE HOUSEWhite House Control Over Frontier AI Access Reshapes the Pecking Order — Microsoft and Oracle Gain, Open-Source Loses6 days agoENERGYMissouri Joins Federal Nuclear Fast-Track and a U.S. Uranium Project Clears Permitting — The Nuclear Supply Chain Is Moving3 weeks agoCRYPTOT. Rowe Price's Active Multi-Token Crypto ETF Is a Fee Story — and a Pressure Test for Bitwise and Grayscale6 days agoMARKETSThe Supreme Court Just Gave Trump Control Over the FTC — What That Means for M&A and Big Tech3 weeks agoWHITE HOUSEWhite House Cybersecurity Clearinghouse Creates a Direct Revenue Line for CrowdStrike, Palantir, and Microsoft6 days agoTRADE & TARIFFSTariff Refunds Are Flowing — Nike and FedEx Are Among the First to See Real Money3 weeks agoENERGYMichigan's Line 5 Permit Renewal Is a Clear Win for Enbridge — and a Setback for Pipeline Opponentslast weekDEFENSEThe U.S.-Iran Ceasefire and $87.6B Pentagon Request Are Two Sides of the Same Defense Spending Boom3 weeks agoDEFENSEPentagon's Laser Weapon Contracts for Drone Defense Open a New Revenue Line for Northrop and L3Harrislast weekHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Just Got a Bigger Market3 weeks agoCRYPTOT. Rowe Price's Active Multi-Token Crypto ETF Is a Fee-War Warning Shot for Bitwise and Grayscalelast weekDEFENSEHegseth's NATO Broadside and Europe Force Review Signal a Shift That Benefits U.S. Primes — at Europe's Expense3 weeks agoENERGYMichigan Renews Enbridge's Line 5 Tunnel Permit, Removing the Biggest Regulatory Overhang on the Stocklast weekCRYPTOBitcoin ETF Outflows Hit $4.3 Billion in June — Coinbase, MARA, and Strategy Are Carrying the Most Risk3 weeks agoTECHBosch's $225M CHIPS Award for Silicon Carbide Puts Wolfspeed and Onsemi on Noticelast weekWHITE HOUSETrump's Quantum Executive Orders Set a 2030 Deadline — and a Spending Clock for IonQ, Rigetti, and the Cybersecurity Stack3 weeks agoENERGYNew Mexico Blocks Oracle's Data Center Gas Pipeline, Exposing the Fragility of Big Tech's Power Build-Outlast weekDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Revenue Line for AeroVironment — and Pressure on Its Rivals3 weeks agoWHITE HOUSEWhite House 'Gold Eagle' AI Cyber Clearinghouse Is a Direct Revenue Signal for CrowdStrike and Palantirlast weekHEALTHCARE & FDAMedicare Starts Covering GLP-1 Weight-Loss Drugs July 1 — Novo Nordisk and Eli Lilly Just Got 67 Million New Potential Customers3 weeks agoDEFENSEPentagon's Laser Weapon Contracts for Drone Defense Hand a Direct Win to Directed-Energy Specialistslast weekENERGYWashington Is Rewriting Nuclear Radiation Safety Rules — Constellation, Vistra, and the SMR Crowd All Win3 weeks agoHEALTHCARE & FDACMS's Proposed 340B Payment Cuts Would Squeeze Hospital Revenue While Helping PBM Rivalslast weekHEALTHCARE & FDAMedicare Is Now Covering Wegovy — Novo Nordisk and Eli Lilly Just Got a Massive New Payer3 weeks agoWHITE HOUSETrump Shrinks Two Utah Monuments by 90%, Opening Land to Mining and Drillinglast weekTECHCommerce Department's AI Model Export Controls Are the Next Nvidia Headwind — and AMD Isn't Immune3 weeks agoENERGYTrump's Nuclear Push Is Driving a Real Uranium Mining Revival — These Are the Stocks That Collectlast weekDEFENSEHegseth's NATO Broadside and European Force Review Put Defense Primes in a Complicated Spot3 weeks agoTRADE & TARIFFSPepsiCo's Tariff Refund Is a Small Win, But It Points to a Broader Cost Relief Story for Consumer Stapleslast weekENERGYThe US-Iran Initial Deal Puts Sanction Relief on the Table — and That's a Headwind for Oil Prices and E&P Stocks3 weeks agoDEFENSEJohnson's $95 Billion Defense Spending Plan Has Lockheed, RTX, and Northrop Written All Over Itlast weekHEALTHCARE & FDAFDA Expands Casgevy to Toddlers — Vertex and CRISPR Therapeutics Just Got a Bigger Market3 weeks agoENERGYPalisades Restart and Trump's Nuclear Push Are Turning Uranium Miners Into a Policy Tradelast weekWHITE HOUSETrump's Quantum Executive Order Sets a Hard Deadline — and Quantum Computing Stocks Are the Immediate Beneficiary3 weeks agoDEFENSEThe UK's £300 Billion Defense Plan Is a Revenue Opportunity for U.S. Contractors — If They Can Win the Bidslast weekTRADE & TARIFFSNike's Tariff Refunds Are a One-Time Boost, Not a Structural Fix — Here's What the Q4 Beat Actually Means3 weeks agoHEALTHCARE & FDAHHS Fraud Crackdown on Medicare Advantage Puts Managed Care Insurers and For-Profit Hospitals on Defenselast weekCRYPTOBitcoin Is Down 33% at Mid-Year and ETF Outflows Hit $4.3B in June — Coinbase and the Miners Are Feeling It3 weeks agoTRADE & TARIFFSBIS Lifts Export Restrictions on UAE — Chip and Defense Tech Sellers Get a New Customerlast weekTRADE & TARIFFSNike's Tariff Refund Windfall Shows How Import-Heavy Brands Can Turn Trade Policy Into a Margin Story3 weeks agoDEFENSENATO Members Racing to 3.5% GDP Defense Spending — U.S. Contractors Are the Biggest Beneficiarieslast weekHEALTHCARE & FDAFDA's BHT and ADA Reassessment Puts Food Additive Users on Notice — and Creates an Opening for Clean-Label Suppliers3 weeks agoTECHThe White House's $2 Billion Quantum Bet Has Clear Winners — and They're Already Publiclast weekENERGYMissouri Joins Federal Nuclear Fast-Track Program, Adding Momentum to the SMR Buildout Trade3 weeks agoWHITE HOUSEESA 'Harm' Definition Rescinded — Extractive Industries Get Regulatory Relief, Conservation Stocks Face Uncertaintylast weekDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Revenue Line for AeroVironment3 weeks agoMARKETSDOJ Kills TransDigm's $960M Deal — The Acquirer Takes the Hit, the Target Gets a Second Lifelast weekHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Get a Bigger Market3 weeks agoCRYPTOThe CLARITY Act Could Redraw Crypto's Regulatory Map — Here's Which Public Names Winlast weekTECHTrump's Post-Quantum Cryptography Executive Order Creates a Compliance Spending Mandate — and Clear Beneficiaries3 weeks agoENERGYPalisades Nuclear Restart and New SMR Plans Put Holtec — and Its Public Suppliers — in the Spotlightlast weekTECHTrump's Quantum Computing Executive Orders Create a Policy Tailwind for a Handful of Public Names3 weeks agoWHITE HOUSETrump's Subpoenas of NYT Reporters Create Legal Overhang for News Publishers — and a Tailwind for First Amendment Litigatorslast weekCRYPTOCrypto Clarity Act Progress and SEC's ETF Rule Review Are the Two Biggest Near-Term Catalysts for Coinbase and Robinhood3 weeks agoTECHThe White House's $2 Billion Quantum Bet Has Clear Stock Winners — and a Cryptography Deadline That Hurts Laggardslast weekDEFENSEThe US-Iran Ceasefire Deal Pressures Oil Prices — and Reshuffles the Defense Trade3 weeks agoDEFENSENATO's 3.5% GDP Spending Push Is a Multi-Year Order Book for Lockheed, RTX, and Northroplast weekDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Payday for AeroVironment3 weeks agoENERGYFederal Proposal to Streamline Nuclear Environmental Reviews Cuts the Biggest Cost for SMR Developerslast weekHEALTHCARE & FDAFDA Expands Casgevy to Children as Young as 2, Widening the Market for Vertex and CRISPR Therapeutics3 weeks agoTRADE & TARIFFSDeepSeek's Custom Chip Gambit Is a Direct Threat to Nvidia's China Revenue — and a Warning for AMDlast weekDEFENSENATO's Spending Surge Is Real — and the US Defense Primes Are the Ones Getting Paid3 weeks agoHEALTHCARE & FDAMedicare Advantage Plans Are Set to Collect $13 Billion in Quality Bonuses — UnitedHealth and Humana Lead the Queuelast weekDEFENSENATO's 'Report Card' Pressure Means Years of European Defense Spending — RTX and Lockheed Are the First Calls3 weeks agoWHITE HOUSEFTC Forces Deere to Open Its Repair Tools — and Hands Independent Shops a Business Modellast weekENERGYU.S.-Iran Initial Deal Eases Sanctions Pressure — Oil Prices Face a Ceiling, E&P Stocks Feel It3 weeks agoHEALTHCARE & FDAFDA Clears Casgevy for Toddlers with Sickle Cell — Vertex and CRISPR Therapeutics Get a Bigger Marketlast weekTECHWhite House Lifts Export Controls on Anthropic's Advanced AI Models — Nvidia and AMD Are the Coattail Trade3 weeks agoCRYPTOVanguard's Crypto Pivot Signals Institutional Capitulation — Coinbase and Robinhood Are the Infrastructure Winnerslast weekENERGYMissouri Joins Federal Nuclear Fast-Track Program as State-Level Momentum Builds — Constellation, Vistra, and Oklo Are the Plays3 weeks agoENERGYFederal Nuclear Push Makes Centrus Energy's HALEU Monopoly More Valuable by the Monthlast weekHEALTHCARE & FDAFDA Clears Casgevy for Toddlers with Sickle Cell — Vertex and CRISPR Therapeutics Get a Bigger Market3 weeks agoHEALTHCARE & FDAFDA Clears Casgevy for Toddlers — Vertex and CRISPR Therapeutics Just Doubled Their Addressable Marketlast weekHEALTHCARE & FDAMedicare Starts Covering GLP-1 Obesity Drugs — Novo Nordisk and Eli Lilly Are the Direct Winners3 weeks agoENERGYUSDA's Revamped Biorefinery Loan Guarantee Program Is a Quiet Tailwind for ADM and Renewable Chemical Producerslast weekCRYPTOSEC Commissioner Signals Crypto Clarity Act Could Pass This Summer — Coinbase and Robinhood Are the Clearest Beneficiaries3 weeks agoHEALTHCARE & FDATrump's Proposed Medicare Drug Savings Rule Puts PBMs in the Crosshairs — and Gives Pharma a Mixed Signallast weekTECHWhite House Quantum Summit and Accelerated PQC Deadlines Create a Spending Runway for IonQ and IBM2 weeks agoCRYPTOThe SEC's 2026 Crypto Regulatory Agenda Is a Green Light for Coinbase and Robinhoodlast weekDEFENSENATO's 3.5% GDP Spending Push Sends a Long-Term Revenue Signal to Raytheon, Lockheed, and Northrop2 weeks agoMARKETSFTC Forces John Deere to Open Its Repair Tools — Farmers Win, Deere's Software Moat Takes a Hitlast weekCRYPTOSEC's Pending Crypto Safe Harbor Rule Is the Clearest Regulatory Tailwind Coinbase Has Seen in Years2 weeks agoTRADE & TARIFFSDeepSeek's Custom Chip Gambit Is a Direct Threat to Nvidia's China Revenue — and a Warning for AMDlast weekHEALTHCARE & FDAMedicare Covering Obesity Drugs for the First Time Is a Direct Volume Catalyst for Novo Nordisk and Eli Lilly2 weeks agoENERGYCommonwealth LNG Permit Moves Forward — Cheniere and ConocoPhillips Are Watching Closelylast weekENERGYCommonwealth LNG Permit Review Opens a New Export Capacity Race — Cheniere Holds the Pole Position2 weeks agoENERGYFederal Proposal to Streamline Nuclear Environmental Reviews Cuts the Clock for SMR Developerslast weekHEALTHCARE & FDAElevance Suing CMS Over Medicare Advantage Stars Is a Warning Sign for the Entire Managed Care Sector2 weeks agoDEFENSENATO's Spending Surge Is Real and Getting Enforced — RTX, Lockheed, and AeroVironment Are the Direct Beneficiarieslast weekHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Get a Bigger Market2 weeks agoMARKETSFTC Forces John Deere to Open Its Repair Ecosystem — and the Aftermarket Parts Industry Wins2 weeks agoENERGYCommonwealth LNG Permit Review Opens — Another Export Terminal in the Queue Benefits the Whole LNG Supply Chain2 weeks agoENERGYFederal Proposal to Streamline Nuclear Environmental Reviews Cuts Years Off the SMR Timeline2 weeks agoTRADE & TARIFFSTariff Tailwinds Are Still Running for U.S. Metals — but the Easy Money in Steel and Aluminum May Already Be Priced2 weeks agoDEFENSENATO's 3.5% GDP Spending Push Is a Multi-Year Order Book for U.S. Defense Primes2 weeks agoTRADE & TARIFFSMcCormick's $28M Tariff Refund Is a One-Time Cushion — the Underlying Cost Pressure Hasn't Gone Away2 weeks agoTECHTrump Accelerates Post-Quantum Encryption Deadlines — and a Handful of Small-Cap Security Firms Are the Direct Beneficiaries2 weeks agoHEALTHCARE & FDAMedicare Starts Covering Obesity Drugs — Novo Nordisk and Eli Lilly Just Got 67 Million New Potential Customers2 weeks ago
1 free article left this week. A free account gets you 4 a week.Go Pro →
Trade & Tariffs

Tariffs on Indian Pharma Are Coming — and U.S. Generic Drug Buyers Will Pay the Bill

The CEO of a leading Indian generics firm says U.S. tariffs will raise generic drug prices, and the math flows directly to U.S. pharmacy chains and patients.

Image: Money Racket
By at Money Racket·Jul 25, 2026
1-YEAR MOVE
+45%−4%
PFE▼3.6%LLY▲43.0%
1-year price move by ticker
TickerCompany1-year change
PFEPfizer−3.6%
LLYEli Lilly+43.0%

The CEO of a major Indian pharmaceutical company warned CNBC that U.S. tariffs will result in higher generic drug prices for American consumers. India supplies roughly 40% of U.S. generic drug volume, and tariffs on pharmaceutical imports would raise input costs across the supply chain.

India supplies 40% of U.S. generic drug volume. Tariffs don't stay at the border — they move through the supply chain and land on the pharmacy counter.

Who cashes in: U.S.-based generic manufacturers with domestic production — Viatris (VTRS) has some U.S. manufacturing, though it's also heavily India-exposed. The cleaner domestic play is Amneal Pharmaceuticals (AMRX), which has a larger share of U.S.-based production relative to peers. Brand-name drug makers like Pfizer PFE, Merck MRK, and Eli Lilly LLY benefit indirectly if generic alternatives become more expensive, as some patients and payers shift back to branded drugs with rebate structures.

Who's exposed: Sun Pharmaceutical Industries, Dr. Reddy's Laboratories (RDY — U.S.-listed ADR), and Teva Pharmaceutical (TEVA), which sources heavily from India, all face margin compression if tariffs raise their cost of goods sold without a corresponding ability to raise prices in a competitive generic market. U.S. pharmacy chains CVS CVS and Walgreens (WBA) face pressure if generic cost inflation squeezes their pharmacy margins or drives customers away from filling prescriptions.

What to watch next: Whether the Trump administration includes pharmaceuticals in its next tariff action or grants a sector exemption. A pharma-specific carve-out would deflate this thesis immediately. Watch for any executive order language on drug tariff exemptions.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $40/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Share

https://moneyracket.com/article/tariffs-generic-drug-prices-india-pharma/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →